Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Long-Term Investments: 2020-2021

Historic Long-Term Investments for Insight Molecular Diagnostics (IMDX) over the last 1 years, with Mar 2021 value amounting to $2.0 million.

  • Insight Molecular Diagnostics' Long-Term Investments fell 80.87% to $2.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $2.0 million, marking a year-over-year decrease of 80.87%. This contributed to the annual value of $13.4 million for FY2020, which is N/A change from last year.
  • Insight Molecular Diagnostics' Long-Term Investments amounted to $2.0 million in Q1 2021, which was down 84.83% from $13.4 million recorded in Q4 2020.
  • In the past 5 years, Insight Molecular Diagnostics' Long-Term Investments ranged from a high of $14.3 million in Q2 2020 and a low of $2.0 million during Q1 2021.
  • Moreover, its 2-year median value for Long-Term Investments was $13.4 million (2020), whereas its average is $10.9 million.
  • Data for Insight Molecular Diagnostics' Long-Term Investments shows a maximum YoY plummeted of 80.87% (in 2021) over the last 5 years.
  • Insight Molecular Diagnostics' Long-Term Investments (Quarterly) stood at $13.4 million in 2020, then slumped by 80.87% to $2.0 million in 2021.
  • Its last three reported values are $2.0 million in Q1 2021, $13.4 million for Q4 2020, and $13.9 million during Q3 2020.